Biophytis Announces Expansion of Patient Recruitment for Part 2 of the Phase 2-3 COVA Trial (“COVA Study”) Following Regulatory Authorities Approvals in France and Belgium - read this article along with other careers information, tips and advice on BioSpace
Biophytis Announces Expansion of Patient Recruitment for Part 2 of the Phase 2-3 COVA Trial (“COVA Study”) Following Regulatory Authorities Approvals in France and Belgium
February 17, 2021 02:00 ET | Source: BIOPHYTIS SA BIOPHYTIS SA Romainville, FRANCE
Clinical centers in France and Belgium will begin recruitment for Part 2 of the COVA Study following authorization from Regulatory Authorities
These approvals follow the previous authorizations obtained from Brazil and the United States in most clinical centers
Interim Analysis of Part 1 is expected in Q1 2021
Results from the full study (Part 1 and Part 2) are expected in Q2 2021
PARIS and CAMBRIDGE, Mass., Feb. 17, 2021 (GLOBE NEWSWIRE) Biophytis SA (NasdaqGS: BPTS; Euronext Growth Paris: ALBPS), a clinical-stage biotechnology company focused on the development of therapeutics that are aimed at slowing the degenerative processes associated with aging and improving f
Biophytis Announces Closing of ADS Offering on Nasdaq Capital Market - Feb 15, 2021 - read this article along with other careers information, tips and advice on BioSpace